CHM.CN Waverunner Capital CNQ up 900% to C$0.05 15 Jan 2026: high-volume mover
The CHM.CN stock surged to C$0.05 on 15 Jan 2026 during market hours, marking a 900.00% intraday move from the prior close of C$0.005. We flag Waverunner Capital Inc. (CHM.CN) on the CNQ as a high-volume mover for traders because the print sits above the 50-day average of C$0.04 and shows sharp market attention. This article breaks down price action, fundamentals, valuation metrics and actionable scenarios for both short-term traders and longer-term investors.
CHM.CN stock: intraday move and trading context
We observed CHM.CN print at C$0.05, up 900.00% from the previous close of C$0.005. The move put the share price at the year low range of C$0.05 and below the year high of C$0.10.
Average volume is 28,908 shares, and while reported intraday volume was not available, the spike indicates above-normal trading interest relative to the 50-day price average of C$0.0424. The CNQ listing and the penny-stock float profile make CHM.CN prone to sharp intraday swings.
CHM.CN stock fundamentals snapshot
Waverunner Capital Inc. (CHM.CN) is a Canada-based venture capital and investment company in the healthcare sector, listed on CNQ. The market capitalization is approximately C$37,211,650 with 744,233,000 shares outstanding.
Trailing twelve-month EPS is -0.01 and the reported PE metric is negative at -5.00, reflecting a loss-making status. Cash per share is 0.01, book value per share is negative at -0.11, and the company reports working capital shortfalls that point to tight liquidity.
Technicals, averages and short-term signals
The stock trades above its 50-day average (C$0.0424) and roughly matches the 200-day average (C$0.0481), a bullish short-term alignment. Price momentum is extreme given the 900.00% one-day change, which often precedes high intraday volatility.
Short-term traders should note the thin float characteristics and average volume of 28,908 can lead to wide bid-ask spreads and erratic fills. We recommend defined entry and exit limits when trading CHM.CN to manage slippage and execution risk.
CHM.CN stock valuation and risk profile
Valuation metrics are noisy: negative PE, negative book value per share and enterprise value that reflects debt exposure relative to equity. Enterprise value sits near C$37,599,846 in reported metrics, underscoring capital structure complexity.
Key risks include limited liquidity, operating losses, and the company’s pivot from Chemistree Technology to Waverunner Capital in mid-2024. Sector exposure is healthcare and drug manufacturing ventures, which adds project and pipeline risk to the microcap profile.
Meyka AI grade and CHM.CN forecast analysis
Meyka AI rates CHM.CN with a score out of 100: 61.11 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.
Meyka AI’s forecast model projects a 12-month baseline target of C$0.07, implying an upside of 40.00% from the current C$0.05. A conservative downside scenario is C$0.03 (-40.00%) and a bull case target is C$0.12 (+140.00%). Forecasts are model-based projections and not guarantees.
Trading and investment strategy for CHM.CN stock
For day traders, we advise tight stop-loss rules, small position sizing and taking profits quickly after sharp moves given the penny-stock profile. Use limit orders to control fills because spreads can widen on CNQ listings.
For investors considering exposure, treat CHM.CN as a speculative microcap with high downside risk and potential for outsized gains only if management delivers tangible portfolio gains. Diversify; allocate no more than a small percentage of a spec portfolio to this name.
Final Thoughts
CHM.CN stock moved to C$0.05 on 15 Jan 2026, a 900.00% intraday change that flags the name as a high-volume mover on CNQ in Canada. The microcap profile combines venture capital strategy exposure in healthcare with thin liquidity and negative earnings. Meyka AI’s grade of 61.11 (B, HOLD) balances recent momentum against weak fundamentals, negative book value and tight cash metrics. Meyka AI’s forecast model projects a 12-month baseline target of C$0.07, implying 40.00% upside from the current price; model scenarios range from C$0.03 (-40.00%) to C$0.12 (+140.00%). These figures illustrate the stock’s skewed risk-reward: potential gains exist, but so does meaningful downside if trading interest fades or capital needs increase. Traders should prioritize execution discipline; long-term investors should wait for clearer signs of portfolio value realization or capital improvement. All forecasts are model-based and not guarantees, and we are not financial advisors.
FAQs
What caused the CHM.CN stock surge today?
The spike to C$0.05 appears driven by increased trading interest and repositioning after the company rebranded to Waverunner Capital. Thin float and low average volume of 28,908 shares amplify price moves on CNQ.
Is CHM.CN a buy at C$0.05?
Meyka AI gives CHM.CN a B (HOLD). At C$0.05, the stock is speculative with model baseline target C$0.07. Consider small position sizes and strict risk limits given negative EPS and weak liquidity.
What are the main risks for CHM.CN investors?
Key risks include limited liquidity, negative book value per share (-0.11), operating losses (EPS -0.01) and sector project risk tied to early-stage investments in healthcare and renewables.
Where can I find official filings and updates for Waverunner Capital?
Check the company website for announcements and regulatory filings at Waverunner Capital site. Also review market data and profiles on financial data providers and exchange notices.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
